title: Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
authors.affiliation: Obesity Medicine and Endocrinology, Salford Royal NHS Foundation Trust and University Teaching Hospital, Salford, UK; Faculty of Medical and Human Sciences, The University of Manchester, Manchester, UK. Electronic address: hanaa.elkhenini@srft.nhs.uk.
authors.forename: Hanaa
authors.initials: H
authors.lastname: Elkhenini
authors.affiliation: Obesity Medicine and Endocrinology, Salford Royal NHS Foundation Trust and University Teaching Hospital, Salford, UK; Faculty of Medical and Human Sciences, The University of Manchester, Manchester, UK.
authors.forename: John P
authors.initials: JP
authors.lastname: New
authors.affiliation: Obesity Medicine and Endocrinology, Salford Royal NHS Foundation Trust and University Teaching Hospital, Salford, UK; Faculty of Medical and Human Sciences, The University of Manchester, Manchester, UK.
authors.forename: Lucinda K M
authors.initials: LK
authors.lastname: Summers
authors.affiliation: Obesity Medicine and Endocrinology, Salford Royal NHS Foundation Trust and University Teaching Hospital, Salford, UK; Faculty of Medical and Human Sciences, The University of Manchester, Manchester, UK.
authors.forename: Akheel A
authors.initials: AA
authors.lastname: Syed
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000069450:Liraglutide; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications* / Q000188:drug therapy*; D015431:Weight Loss / Q000187:drug effects*; D055815:Young Adult
chemical_list: D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1
keywords: Glucagon-like peptide-1 receptor agonists; Obesity; Weight loss